Patented Technology:
Vilacto Bio holds the worldwide patent for LACTOACTIVE iTHER®.
Helping the Body Beat Disease:
LACTOACTIVE iTHER® is a new LACTOACTIVE® variant built on our latest refinement techniques and even more precise and targeted fractionation. The compound will enable doctors to use injection, implantable and other delivery systems to send the richest form of colostrum available deeper into the body, where it is trained to penetrate cell walls and help the body fight diseases.
LACTOACTIVE iTHER® compound:
The LACTOACTIVE iTHER® compound will also enable the pharmaceutical companies we partner with to embed our potent compounds in their own immunotherapy and vaccine innovations. Emerging therapies for treating cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and vitiligo all stand to benefit.
Unique double action
Produced at Vilacto Bio’s own facilities in Denmark, LACTOACTIVE iTHER® works by ultra-refined bovine colostrum with other substances to:
- Supplement the body’s antibodies with those contained in the compound
- Stimulate the body’s own ability to produce disease-fighting antibodies
Thanks to is nanoparticle form, the compound also acts as an injectable nanoparticle drug delivery system (NDDS), able to penetrate affected cell walls and enter the cytoplasm to do its work.
LACTOACTIVE iTHER® in details
LACTOACTIVE iTHER® is a type of nanotherapy with particles that range from 10 nm to 300 nm in diameter.
The particles consist of refined colostrum and other ingredients that both contain vital antibodies and stimulate the immune system to fight diseases.
Other demonstrable benefits include anti-inflammation and growth-stimulation properties.
LACTOACTIVE iTHER® can be directed into the affected cells, where it boosts the immune system’s response to the disease in question.
No other biotech firm has managed to “weaponize” colostrum so effectively.
Vilacto Bio holds the worldwide patent for LACTOACTIVE iTHER®.
About Colostrum
Help put the power of colostrum to work
In early 2018, Vilacto Bio invested in a major upgrade to its Denmark production facility, which can now accommodate the new compound formulations and smaller particle sizes that LACTOACTIVE iTHER® requires. In the meantime, Vilacto Bio representatives have begun engaging colostrum and nanomedicine research groups and potential partners in the pharmaceutical industry to explore opportunities for collaboration.
Invest in Viacto Bio and help improve emerging immunotherapies and antibody vaccines with antibody- and antigen-rich colostrum in nanoparticle form.